Pub. Date : 2021 Apr
PMID : 33078278
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |
| 2 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |
| 3 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |
| 4 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |
| 5 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |
| 6 | Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. | Idarubicin | CD34 molecule | Homo sapiens |